最准的六合彩论坛

By developing the Alzfinder platform rooted in 最准的六合彩论坛 research, medtech startup chronostics is revolutionizing Alzheimer's clinical trials, rescuing promising drugs from the pharmaceutical graveyard.

Chronostics鈩� is a medtech startup stemming from 最准的六合彩论坛 research seeking to revolutionize computational medicine and healthcare. They specialise in building and deploying data-driven models to empower clinical trials and healthcare initiatives, with a key focus on unravelling the heterogeneity of age-related chronic conditions 鈥� a high priority challenge in modern medicine with a significant socioeconomic burden.

Upon acceptance to the CDI Impact Accelerator, chronostics was particularly impressed by AWS's global scalability, which can support the company鈥檚 ambitions for growth. The CDI provided vital cloud DevOps support to propel chronostics toward establishing a scalable computational infrastructure to meet customer demand.

The challenge听

Alzheimer鈥檚 disease is the leading cause of dementia and currently ranks among the top ten contributors to global mortality. Its associated care expenses alone cost the global economy over $1.3T per year and is projected to more than double by 2050 according to the World Health Organisation (WHO, 2021a; WHO 2021b). Finding a drug that works on even a subset of patients could save billions of dollars and prevent untold heartache. Clinical decision-making in Alzheimer鈥檚 disease is a formidable challenge, particularly in clinical trials of new drugs.

Despite over $43 billion invested over the past 25+ years, 99% of promising Alzheimer鈥檚 drugs have been relegated to the pharmaceutical graveyard, in part because it鈥檚 seemingly impossible to predict who will and won鈥檛 benefit from a drug 鈥� and when. This exerts immense stress upon clinical researchers tasked with trial recruitment and will similarly impact patient management with a handful of new drugs entering the market in the past two years.

The solution

Numerous academic research papers propose novel methodologies, claiming potential impact for neurological clinical trials. However, commitment to backing up these claims by building something is scarce. In contrast, the visionary founder team of chronostics embraced an alternative path. Motivated by their own research findings at 最准的六合彩论坛, which revealed significant differences in disease progression subtypes, they established a company with a clear mission to effect transformative change. Their aim is to optimise drug development efficiency through targeting the right patients and the right time for clinical trials, leveraging proprietary technologies developed by the company.

The AlzFinder platform听

The chronostics solution 鈥淎lzFinder鈩⑩�� can reduce uncertainty in patient management and recruitment for clinical trials in Alzheimer鈥檚 disease. From a single brain scan uploaded to secure servers in the AWS cloud, AlzFinder can return a quantitative report and patient risk profile overnight! Additionally, the chronostics team can bring expert humans into the loop to provide bespoke insights and decision support. More generally, chronostics leverages their unique combination of expertise in mathematical modelling and unsupervised machine learning to build quantitative data-driven solutions to support clinical decisions and inform on clinical trial design, starting in neurological diseases.

The AlzFinder鈩� technology is built on a decade of world-leading research into Alzheimer鈥檚 disease progression. chronostics鈩� has worked with pharmaceutical companies to validate the technology that underpins AlzFinder鈩� on data from past clinical trials, where they found differential treatment response in AlzFinder鈩� subgroups. This paves the way for revival of zombie drugs from the pharmaceutical graveyard, novel clinical trial designs empowered by AlzFinder鈩� (with huge time and cost savings, and reduced patient burden), and lucrative companion diagnostic products on the front line of healthcare worldwide.

CDI Impact听

With CDI support, chronostics鈩� embarked on its journey into cloud-based computing infrastructure, starting with a semi-automated service for analysing large datasets from unsuccessful clinical trials. The cloud DevOps support provided by 最准的六合彩论坛 Advanced Research Computing software engineers and AWS solutions architects was invaluable for establishing a robust code infrastructure backend that enables chronostics鈩� to build and launch multiple products and services independently.

Furthermore, with a strong focus on the impact for end users of chronostics鈩⑩�� solution, their participation in the CDI programme has played a pivotal role in transforming their customer service approach. They have shifted from labour-intensive manual analyses to a fully cloud-based semi-automated solution, resulting in more efficient and streamlined processes for serving their customers.

Dr Neil Oxtoby, CEO and Co-founder of chronostics鈩�, summarises his experience with the CDI:

鈥淎s the only chronostics鈩� founder on this CDI journey, I had to balance both technical and business development on my own. Having already made considerable progress on business development, I benefited most from CDI鈥檚 technical support related to cloud development. I went from being a complete novice to having a basic competency in Cloud DevOps! Without the CDI鈥檚 support I would not have had the bandwidth to achieve the near full-functioning cloud infrastructure I developed for the first product at chronostics鈩�. Thank you to the entire CDI team!鈥�

References

• World Health Organisation. (2021a). Global status report on the public health response to dementia. [online] Available at: .
• World Health Organisation. (2021b). Dementia: a public health priority. [online] Available at: .
  听